HONG KONG – Chinese firm Cure Genetics Co. Ltd., of Suzhou, has secured $17 million in series A financing to advance its gene-editing and delivery platform to treat easy-to-relapse or hard-to-treat cancers and genetic diseases.
HONG KONG – China's Hangzhou Qihan Bio Inc. has completed a series A financing to raise $7.8 million for the development of xenotransplantation procedures, engineering pig organs to be transplanted into humans.
HONG KONG – China's Hangzhou Qihan Bio Inc. has completed a series A financing to raise $7.8 million for the development of xenotransplantation procedures, engineering pig organs to be transplanted into humans.
HONG KONG – Shanghai Green Valley (Group) Co. Ltd. is gearing up to file for approval in China later this year after its sodium oligomannurarate (GV-971) capsules significantly improved cognition among patients with mild to moderate Alzheimer's disease (AD) in phase III trials.
HONG KONG – Chinese biopharmaceutical firm Beigene Ltd. filed with the Hong Kong Stock Exchange (HKEX) for a monster IPO that could raise more than $1 billion. It is the second biotech firm to seek an HKEX listing after Hangzhou-based Ascletis Pharma Inc. priced a nearly $400 million offering earlier this month.
HONG KONG – Sinovant Sciences Ltd., of Shanghai, has joined hands with U.S. firm Renexxion LLC to develop naronapride, an investigational gastrointestinal prokinetic for treating irritable bowel syndrome with constipation (IBS-C).
HONG KONG – Sinovant Sciences Ltd., of Shanghai, has joined hands with U.S. firm Renexxion LLC to develop naronapride, an investigational gastrointestinal prokinetic for treating irritable bowel syndrome with constipation (IBS-C).
HONG KONG – Chinese biopharmaceutical firm Beigene Ltd. filed with the Hong Kong Stock Exchange (HKEX) for a monster IPO that could raise more than $1 billion. It is the second biotech firm to seek an HKEX listing after Hangzhou-based Ascletis Pharma Inc. priced a nearly $400 million offering earlier this month.
